Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

EU Laws On Medicines Supply To Northern Ireland Move Closer

Executive Summary

Draft legislation that would avoid post-Brexit regulatory problems for medicines moving between Great Britain and Northern Ireland is on course for formal adoption.

You may also be interested in...



Navigating The UK's Post-Brexit Regulatory Complexities

The UK regulator explains the new requirements for batch testing and release in Great Britain and Northern Ireland, what's involved in importing clinical trial drugs to Northern Ireland, and what factors determine the location of the Qualified Person.

French Increase Penalties On Firms Breaching Drug Supply Rules

Pharma firms in France are facing tougher sanctions from October if they fail to honor their obligations in terms of anticipating and managing potential or actual drug shortages.

Firms Advised To Prepare Now For New EU Patent System

After many delays and disagreements, Europe’s Unified Patent Court is expected to open its doors in the first quarter of 2023, offering a more cost-effective option for patent protection and dispute settlement in the EU. The new system includes the possibility of taking out a “unitary patent” offering EU protection in practically all the EU member states. A guide to the key points of the new system is shown below.

Topics

Latest News
See All
UsernamePublicRestriction

Register

GB151722

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel